BCG
12
0
2
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
16.7%
2 terminated out of 12 trials
66.7%
-19.8% vs benchmark
50%
6 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
BCG for Therapeutic Use Phase Ⅲ Clinical Trial
Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?
BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
Vitamin D3 For CGD Patients With BCGosis/Itis
Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
SARS-CoV-2/COVID-19 Infection Among Health Care Workers
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial
Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)